Stealth BioTherapeutics CEO discusses surprise adcomm support for ultra-rare disease drug

Zachary Brennan

Senior Editor

This week, Stealth BioTherapeutics CEO Reenie McCarthy faced a seemingly insurmountable roadblock with the company’s drug for the ultra-rare, fatal mitochondrial disease Barth syndrome. FDA …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Stealth BioTherapeutics CEO discusses surprise adcomm support for ultra-rare disease drug

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

CBER's deputy director departs as staff shakeup continues

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

FDA approves first drug to treat ultra-rare lipid storage disease

Will CRISPR matter?

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Stealth Bio­Ther­a­peu­tics CEO dis­cuss­es sur­prise ad­comm sup­port for ul­tra-rare dis­ease drug

Senior Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Stealth BioTherapeutics CEO discusses surprise adcomm support for ultra-rare disease drug